Thomas Martin Selected Research

B-Cell Maturation Antigen

3/2024	Salvage Therapies including Retreatment with BCMA-directed Approaches Following BCMA CAR-T Relapses for Multiple Myeloma.
12/2023	Teclistamab impairs humoral immunity in heavily pretreated MM patients: importance of immunoglobulin supplementation.
1/2023	Safety and Efficacy of BCMA CAR-T Cell Therapy in Older Patients With Multiple Myeloma.
1/2023	Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents.
1/2023	Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up.
12/2022	Infectious complications in patients with relapsed refractory multiple myeloma after BCMA CAR T-cell therapy.
12/2022	Health-related quality of life in patients given ciltacabtagene autoleucel for relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b-2, open-label study.
1/2022	Comparison of Cilta-cel, an Anti-BCMA CAR-T Cell Therapy, Versus Conventional Treatment in Patients With Relapsed/Refractory Multiple Myeloma.
1/2021	Early Dynamics and Depth of Response in Multiple Myeloma Patients Treated With BCMA CAR-T Cells.
1/2021	Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Thomas Martin Research Topics

Disease

50	Multiple Myeloma 03/2024 - 03/2006
14	Neoplasms (Cancer) 06/2023 - 04/2002
7	Residual Neoplasm 03/2024 - 01/2019
7	Prostatic Neoplasms (Prostate Cancer) 01/2021 - 04/2004
5	Disease Progression 03/2024 - 05/2012
4	Infections 12/2023 - 02/2022
4	Obstructive Sleep Apnea 02/2014 - 01/2011
3	Neutropenia 12/2022 - 07/2007
3	Chronic Obstructive Pulmonary Disease (COPD) 02/2019 - 04/2002
3	Hypoxia (Hypoxemia) 08/2013 - 01/2011
2	Cytokine Release Syndrome 12/2023 - 01/2023
2	cell-associated neurotoxicity 12/2023 - 01/2023
2	Amyloidosis 01/2023 - 10/2022
2	Body Weight (Weight, Body) 11/2022 - 04/2002
2	Infarction (Infarctions) 01/2020 - 09/2011
2	Hyperoxia 01/2018 - 04/2012
2	Inflammation (Inflammations) 12/2015 - 01/2013
1	Chromosome Aberrations (Chromosome Abnormalities) 03/2024
1	Brain Death (Brain Dead) 01/2024
1	Graft vs Host Disease (Graft-Versus-Host Disease) 12/2023
1	Hemorrhage 11/2023
1	COVID-19 05/2023
1	B-Cell Lymphoma (Lymphoma, B Cell) 01/2023
1	Delirium 01/2023
1	Agammaglobulinemia (Hypogammaglobulinemia) 01/2023
1	Cytopenia 01/2023
1	Lymphopenia (Lymphocytopenia) 12/2022
1	Plasmacytoma 11/2022
1	Thromboembolism 01/2022
1	Frailty 09/2021
1	Renal Cell Carcinoma (Grawitz Tumor) 09/2021
1	Gingivitis 06/2021
1	Urinary Bladder Neoplasms (Bladder Cancer) 01/2021
1	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 01/2021

Drug/Important Bio-Agent (IBA)

18	isatuximabIBA 03/2024 - 01/2017
16	carfilzomibIBA 03/2024 - 10/2012
15	Dexamethasone (Maxidex)FDA LinkGeneric 03/2024 - 01/2017
12	Chimeric Antigen ReceptorsIBA 03/2024 - 01/2021
10	B-Cell Maturation AntigenIBA 03/2024 - 01/2021
9	Proteasome InhibitorsIBA 01/2023 - 10/2012
9	Monoclonal AntibodiesIBA 11/2022 - 01/2017
8	bis(3- bis(4- chlorophenyl)methyl- 4- dimethylaminophenyl)amineIBA 03/2024 - 01/2021
5	Proteins (Proteins, Gene)FDA Link 06/2023 - 10/2003
5	Lenalidomide (CC 5013)FDA Link 01/2022 - 05/2012
4	VaccinesIBA 12/2023 - 10/2003
4	LeptinIBA 02/2014 - 01/2011
3	Messenger RNA (mRNA)IBA 05/2023 - 01/2003
3	Immunoglobulins (Immunoglobulin)IBA 02/2022 - 08/2013
2	Bispecific AntibodiesIBA 12/2023 - 01/2023
2	Heparin (Liquaemin)FDA LinkGeneric 11/2023 - 01/2020
2	AntigensIBA 05/2023 - 09/2004
2	Immunoglobulin G (IgG)IBA 01/2023 - 10/2003
2	Immunoconjugates (Immunoconjugate)IBA 01/2023 - 11/2015
2	Immunomodulating AgentsIBA 01/2023 - 01/2022
2	Single-Domain AntibodiesIBA 12/2022 - 01/2021
2	pomalidomideIBA 11/2022 - 01/2021
2	daratumumabIBA 11/2022 - 10/2022
2	antineoplaston A10 (A 10)IBA 01/2022 - 03/2019
2	Etoposide (VP 16)FDA LinkGeneric 01/2021 - 03/2006
2	Cytarabine (Cytosar-U)FDA LinkGeneric 01/2021 - 01/2019
2	Proteasome Endopeptidase Complex (Proteasome)IBA 12/2020 - 01/2019
2	Oxygen (Dioxygen)IBA 02/2019 - 12/2018
2	Interleukin-6 (Interleukin 6)IBA 02/2019 - 11/2003
2	PanobinostatIBA 01/2019 - 01/2019
2	Reactive Oxygen Species (Oxygen Radicals)IBA 08/2013 - 03/2013
2	Tissue Kallikreins (Tissue Kallikrein)IBA 09/2004 - 01/2003
1	Adenosine Monophosphate (AMP)IBA 03/2024
1	Intravenous Immunoglobulins (IVIG)FDA Link 12/2023
1	Adrenal Cortex Hormones (Corticosteroids)IBA 11/2023
1	Enoxaparin (Lovenox)FDA LinkGeneric 11/2023
1	2019-nCoV Vaccine mRNA-1273IBA 05/2023
1	BNT162 VaccineIBA 05/2023
1	COVID-19 VaccinesIBA 05/2023
1	Recombinant ProteinsIBA 05/2023
1	N-(2-cyanoethylene)urea (BA 1)IBA 05/2023
1	Combined VaccinesIBA 05/2023
1	Amyloid (Amyloid Fibrils)IBA 01/2023
1	Dihydrotachysterol (AT 10)IBA 01/2023
1	lysine(6)- glutaryl- 2- (hydroxymethyl)anthraquinone LHRH (T 98)IBA 12/2022
1	Thalidomide (Thalomid)FDA Link 01/2022
1	Indicators and Reagents (Reagents)IBA 09/2021
1	Ointments (Pastes)IBA 06/2021
1	carboxyl radical (COO-)IBA 01/2021
1	ofatumumab FDA Link 01/2021

Therapy/Procedure

35	Therapeutics 03/2024 - 10/2003
7	Drug Therapy (Chemotherapy) 06/2023 - 01/2006
6	Radiotherapy 01/2021 - 10/2002
5	Brachytherapy 03/2013 - 07/2003
3	Stem Cell Transplantation 01/2021 - 05/2012
2	Transplantation 01/2024 - 10/2003
2	Aftercare (After-Treatment) 06/2023 - 05/2003
2	Nephrectomy 09/2021 - 10/2020
2	Catheters 12/2020 - 07/2003
2	Injections 12/2015 - 06/2004
2	Hematopoietic Stem Cell Transplantation 05/2012 - 10/2003
1	Salvage Therapy 03/2024
1	Retreatment 03/2024
1	Blood Component Removal (Apheresis) 12/2023
1	Subcutaneous Injections 11/2022
1	Cell Transplantation 01/2021